Giuseppe
Emeritus
J Infect Dis. 2009 Mar 1;199(5):711-716.
A Live Attenuated H9N2 Influenza Vaccine Is Well Tolerated and Immunogenic in Healthy Adults.
Karron RA, Callahan K, Luke C, Thumar B, McAuliffe J, Schappell E, Joseph T, Coelingh K, Jin H, Kemble G, Murphy BR, Subbarao K. - 1Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, 2Laboratory of Infectious Diseases, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, and 3MedImmune, Gaithersburg, Maryland.
Development of live attenuated influenza vaccines (LAIV) against avian strains with pandemic potential is an important public-health strategy. Either 1 or 2 10(7)-TCID(50) doses of H9N2 LAIV A/chicken/Hong Kong/G9/97 were administered intranasally to 50 adults in isolation; 41 participants were H9N2 seronegative, 24 of whom received 2 doses.
The vaccine was well tolerated; vaccine shedding was minimal.
After 2 doses, 92% of H9-seronegative participants had 4-fold increases in hemagglutination-inhibition antibody, and 79% had 4-fold increases in neutralizing antibody; 100% had responses detected by at least 1 assay. Although replication of the H9N2 LAIV was restricted, 2 doses were immunogenic in H9N2-seronegative adults.
Trial registration. ClinicalTrials.gov identifier: NCT00110279 .
PMID: 19210163 [PubMed - as supplied by publisher]
-
------
A Live Attenuated H9N2 Influenza Vaccine Is Well Tolerated and Immunogenic in Healthy Adults.
Karron RA, Callahan K, Luke C, Thumar B, McAuliffe J, Schappell E, Joseph T, Coelingh K, Jin H, Kemble G, Murphy BR, Subbarao K. - 1Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, 2Laboratory of Infectious Diseases, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, and 3MedImmune, Gaithersburg, Maryland.
Development of live attenuated influenza vaccines (LAIV) against avian strains with pandemic potential is an important public-health strategy. Either 1 or 2 10(7)-TCID(50) doses of H9N2 LAIV A/chicken/Hong Kong/G9/97 were administered intranasally to 50 adults in isolation; 41 participants were H9N2 seronegative, 24 of whom received 2 doses.
The vaccine was well tolerated; vaccine shedding was minimal.
After 2 doses, 92% of H9-seronegative participants had 4-fold increases in hemagglutination-inhibition antibody, and 79% had 4-fold increases in neutralizing antibody; 100% had responses detected by at least 1 assay. Although replication of the H9N2 LAIV was restricted, 2 doses were immunogenic in H9N2-seronegative adults.
Trial registration. ClinicalTrials.gov identifier: NCT00110279 .
PMID: 19210163 [PubMed - as supplied by publisher]
-
------